In The News

Generic Approvals Up 28% Amid Drug Pricing Concerns

BioWorld

26 Aug 2019

Morrison & Foerster partner Bethany Hills discussed with BioWorld the increase in FDA approvals of abbreviated new drug applications, including first-time generics.

“This is clearly part of the overall Trump administration’s drug pricing plan,” Bethany said, adding that increasing the availability of generics “does seem to be the easiest to accomplish through the existing regulatory framework. And it does seem to be the one drug pricing component…that has an economic model behind it that makes sense.”

Bethany also noted a significant amount of government work being done in terms of “enforcing the competition laws and trying to minimize the pay-for-delay situation or other activities that could be used to minimize the generic entry on the market.”

Close

Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.